Predicine
Predicine is a Silicon Valley-based molecular insights company dedicated to advancing precision medicine in oncology. We pioneer proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy, enabling minimally invasive molecular diagnostics for treatment selection, therapy response, minimal residual disease (MRD) monitoring, and early cancer detection. Our portfolio includes NGS assays for blood, urine, and tissue, offered through centralized lab testing and decentralized kitted solutions, all designed for globally harmonized use in research, clinical investigation, and companion diagnostic (CDx) development. With operations in Silicon Valley, Houston, Chicago, and Shanghai, Predicine partners with leading biopharma companies, institutions, and governments to support global clinical trials and CDx development. Predicine collaborates with Janssen on liquid biopsy CDx development in bladder cancer.Â
